Literature DB >> 32699136

P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors.

Andrea Romagnani1, Elsa Rottoli1,2, Emilia Maria Cristina Mazza3, Tanja Rezzonico-Jost1, Benedetta De Ponte Conti1,2, Michele Proietti1, Michela Perotti1,4, Elisa Civanelli1,2, Lisa Perruzza1, Alberico L Catapano5,6, Andrea Baragetti5, Elena Tenedini7, Enrico Tagliafico7, Simonetta Falzoni8, Francesco Di Virgilio8, Giuseppe Danilo Norata5, Silvio Bicciato3, Fabio Grassi9,2,10.   

Abstract

Extracellular ATP (eATP) is a signaling molecule that variably affects all cells of the immune system either directly or after hydrolysis to adenosine. Although eATP is virtually absent in the interstitium of normal tissues, it can be present in the hundreds of micromolar range in tumors, a concentration compatible with activation of the ATP-gated ionotropic P2X7 receptor. Here, we show that P2X7 activity in tumor-infiltrating lymphocytes (TIL) induces cellular senescence and limits tumor suppression. P2X7 stimulation affected cell cycling of effector T cells and resulted in generation of mitochondrial reactive oxygen species and p38 MAPK-dependent upregulation of cyclin-dependent kinase inhibitor 1A (Cdkn1a, encoding for p21Waf1/Cip1). Lack of P2X7 promoted a transcriptional signature that correlated with enhanced cytotoxic T-cell response in human solid tumors. In mice, transfer of tumor-specific T cells with deletion of P2rx7 significantly reduced tumor growth and extended survival. Collectively, these findings uncover a purinergic checkpoint that can be targeted to improve the efficacy of cancer immunotherapy strategies. SIGNIFICANCE: These findings suggest that the purinergic checkpoint P2X7 may be targeted to enhance T-cell-mediated cancer immunotherapy and improve T effector cell accumulation in the tumor microenvironment. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/18/3906/F1.large.jpg. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32699136      PMCID: PMC7611351          DOI: 10.1158/0008-5472.CAN-19-3807

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  57 in total

1.  Significance analysis of microarrays applied to the ionizing radiation response.

Authors:  V G Tusher; R Tibshirani; G Chu
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

2.  Purinergic P2X7 receptor drives T cell lineage choice and shapes peripheral γδ cells.

Authors:  Michela Frascoli; Jessica Marcandalli; Ursula Schenk; Fabio Grassi
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

3.  Transient activation of p53 in G2 phase is sufficient to induce senescence.

Authors:  Lenno Krenning; Femke M Feringa; Indra A Shaltiel; Jeroen van den Berg; René H Medema
Journal:  Mol Cell       Date:  2014-06-05       Impact factor: 17.970

4.  Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer.

Authors:  Anusha-Preethi Ganesan; James Clarke; Oliver Wood; Eva M Garrido-Martin; Serena J Chee; Toby Mellows; Daniela Samaniego-Castruita; Divya Singh; Grégory Seumois; Aiman Alzetani; Edwin Woo; Peter S Friedmann; Emma V King; Gareth J Thomas; Tilman Sanchez-Elsner; Pandurangan Vijayanand; Christian H Ottensmeier
Journal:  Nat Immunol       Date:  2017-06-19       Impact factor: 25.606

5.  Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.

Authors:  Nabil Ahmed; Vita S Brawley; Meenakshi Hegde; Catherine Robertson; Alexia Ghazi; Claudia Gerken; Enli Liu; Olga Dakhova; Aidin Ashoori; Amanda Corder; Tara Gray; Meng-Fen Wu; Hao Liu; John Hicks; Nino Rainusso; Gianpietro Dotti; Zhuyong Mei; Bambi Grilley; Adrian Gee; Cliona M Rooney; Malcolm K Brenner; Helen E Heslop; Winfried S Wels; Lisa L Wang; Peter Anderson; Stephen Gottschalk
Journal:  J Clin Oncol       Date:  2015-03-23       Impact factor: 44.544

6.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

7.  P2X7 receptor channels allow direct permeation of nanometer-sized dyes.

Authors:  Liam E Browne; Vincent Compan; Laricia Bragg; R Alan North
Journal:  J Neurosci       Date:  2013-02-20       Impact factor: 6.167

Review 8.  Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.

Authors:  Ilaria Marigo; Luigi Dolcetti; Paolo Serafini; Paola Zanovello; Vincenzo Bronte
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

Review 9.  Deciphering and reversing tumor immune suppression.

Authors:  Greg T Motz; George Coukos
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

10.  P2X7 receptor restrains pathogenic Tfh cell generation in systemic lupus erythematosus.

Authors:  Caterina E Faliti; Roberta Gualtierotti; Elsa Rottoli; Maria Gerosa; Lisa Perruzza; Andrea Romagnani; Giovanni Pellegrini; Benedetta De Ponte Conti; Riccardo L Rossi; Marco Idzko; Emilia M C Mazza; Silvio Bicciato; Elisabetta Traggiai; Pier Luigi Meroni; Fabio Grassi
Journal:  J Exp Med       Date:  2019-01-17       Impact factor: 14.307

View more
  8 in total

1.  P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy.

Authors:  Kelsey M Wanhainen; Changwei Peng; Maggie H Zhou; Bruna de Gois Macedo; Stephen O'Flanagan; Tingyuan Yang; Ameeta Kelekar; Brandon J Burbach; Henrique Borges da Silva; Stephen C Jameson
Journal:  Cancer Immunol Res       Date:  2022-07-01       Impact factor: 12.020

2.  Machine Learning-Based Integration Develops a Pyroptosis-Related lncRNA Model to Enhance the Predicted Value of Low-Grade Glioma Patients.

Authors:  Jie Wu; Lichun Lu; Chen Wang; Feng Jiang
Journal:  J Oncol       Date:  2022-05-19       Impact factor: 4.501

Review 3.  Metabolic regulation of tissue-resident memory CD8+ T cells.

Authors:  Trupti Vardam-Kaur; Jie Sun; Henrique Borges da Silva
Journal:  Curr Opin Pharmacol       Date:  2021-03-11       Impact factor: 5.547

4.  Prognostic Value of a Pyroptosis-Related Long Noncoding RNA Signature Associated with Osteosarcoma Microenvironment.

Authors:  Xinxin Bu; Jiuxiang Liu; Rong Ding; Zhi Li
Journal:  J Oncol       Date:  2021-11-11       Impact factor: 4.375

Review 5.  A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.

Authors:  Djo Hasan; Atsuko Shono; Coenraad K van Kalken; Peter J van der Spek; Eric P Krenning; Toru Kotani
Journal:  Purinergic Signal       Date:  2021-11-10       Impact factor: 3.765

Review 6.  P2 Receptors: Novel Disease Markers and Metabolic Checkpoints in Immune Cells.

Authors:  Valentina Vultaggio-Poma; Francesco Di Virgilio
Journal:  Biomolecules       Date:  2022-07-14

Review 7.  To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question.

Authors:  Serena Janho Dit Hreich; Jonathan Benzaquen; Paul Hofman; Valérie Vouret-Craviari
Journal:  Purinergic Signal       Date:  2021-08-04       Impact factor: 3.765

Review 8.  P2X7 is a cytotoxic receptor….maybe not: implications for cancer.

Authors:  Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2020-10-04       Impact factor: 3.765

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.